Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 12.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,903 shares of the biotechnology company’s stock after selling 1,107 shares during the period. […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Blueprint Medicines (NASDAQ:BPMC – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday, TipRanks reports. They presently have a $100.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 101.29% from the company’s […]
Analysts expect Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) to report sales of $1.05 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Homology Medicines’ earnings, with the highest sales estimate coming in at $1.30 million and the lowest estimate coming in at $800,000.00. Homology Medicines posted sales […]